Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

PACB

0.00

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ: PACB) with a Underweight and raises the price target from $1 to $1.5.